Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial

The Lancet

Volumn 375, Issue 9715, 2010, Pages 641-648

  Gore, Martin E ^a   Griffin, Clare L ^b   Hancock, Barry ^c   Patel, Poulam M ^d   Pyle, Lynda ^a   Aitchison, Michael ^e   James, Nicholas ^f   Oliver, Roderick TD ^g   Mardiak, Jozef ^h   Hussain, Tahera ^b   Sylvester, Richard ⁱ   Parmar, Mahesh KB ^b   Royston, Patrick ^b   Mulders, Peter FA ^j  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c WESTON PARK HOSPITAL   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^h CANCER RESEARCH INSTITUTE   (Slovakia)

ⁱ EORTC DATA CENTER   (Belgium)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; INTERLEUKIN 2; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAZARD RATIO; HUMAN; HYPOTENSION; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; LETHARGY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; TREATMENT OUTCOME; VOMITING;

EID: 76749116183     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61921-8     Document Type: Article

References (30)

1. Ferlay J., Bray F., Pisani P., and Parkin D.M. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0 (2004), IARCPress, Lyon
2. De Mulder P.H., van Herpen C.M., and Mulders P.A. Current treatment of renal cell carcinoma. Ann Oncol 15 suppl 4 (2004) 319-328
3. Harkins D, Krapcho M, Mariotto A, et al, eds. National Cancer Institute. SEER cancer statistics review, 1975-2002. http://seer.cancer.gov/csr/1975_2002/ (accessed Feb 15, 2007).
4. Kriegmair M., Oberneder R., and Hofstetter A. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 45 (1995) 758-762
5. Pyrhönen S., Salminen E., Ruutu M., et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17 (1999) 2859-2867
6. Steineck G., Strander H., Carbin B.E., et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol 29 (1990) 155-162
7. Coppin C., Porzsolt F., Awa A., Kumpf J., Goldman A., and Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 1 (2005) CD001425.
8. Medical Research Council Renal Cancer Collaborators. (1999) Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353 (1999) 14-17
9. Negrier S., Perol D., Ravaud A., et al., for the French Immunotherapy Intergroup. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110 (2007) 2468-2477
10. Jones M., Philip T., Palmer P., et al. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother Radiopharm 8 (1993) 275-288
11. Fossa S., Jones M., Johnson P., et al. Interferon-alpha and survival in renal cell cancer. Br J Urol 76 (1995) 286-290
12. Motzer R.J., Bacik J., Murphy B.A., Russo P., and Mazumdar M. Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma. J Clin Oncol 20 (2002) 289-296
13. Fisher R.I., Rosenberg S.A., and Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6 (2000) S55-S57
14. Fyfe G., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., and Louie A.C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13 (1995) 688-696
15. McDermott D.F., Regan M.M., Clark J.I., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133-141
16. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21 (2003) 3127-3132
17. Rosenberg S.A., Yang J.C., White D.E., and Steinberg S.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 228 (1998) 307-319
18. Figlin R., Gitlitz B., Franklin J., et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am 3 (1997) S92-S97
19. Atkins M.B., Regan M., and McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 10 (2004) 6342S-6346S
20. Atzpodien J., Kirchner H., Illiger H.J., et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 85 (2001) 1130-1136
21. Atzopdien J., Kirchner H., Jonas U., et al. Interleukin-2 and interferon alfa-2a based immunotherapy in advanced renal cell carcinoma: a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22 (2004) 1188-1194
22. Royston P. Flexible parametric alternatives to the Cox model, and more. Stata J 1 (2001) 1-28
23. Royston P., and Parmar M. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 21 (2002) 2175-2197
24. Royston P., and Sauerbrei W. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med 23 (2004) 2509-2525
25. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., and Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
26. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
27. Escudier B., Pluzanska A., Koralewski P., et al., for the AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
28. Escudier B., Szczylik C., Hutson T.E., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27 (2009) 1280-1289
29. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27 (2009) 3584-3590
30. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281